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Bisphosphonate is the collective name for compounds in which the backbone of 
pyrophosphoric acid, a P-O-P structure, is converted to chemically stable P-C-P, and this 
structure shows the affinity of bisphosphonate for bone hydroxyapatite in the body (Fleisch 
et al. 2002). Administered bisphosphonate preparations (BPs) transfer to and deposit in 
bone, exhibiting a bone resorption-inhibitory effect. The chemical structure of the side chain 
bound to the carbon atom of P-C-P markedly influences bisphosphonate activity, and, 
particularly, side chains containing nitrogen molecules not only markedly increase the 
affinity for HA but also bone resorption-inhibitory activity (Migliorati et al. 2005). Because 
of this potent bone resorption-inhibitory effect, BPs are the first-choice treatment for 
osteoporosis worldwide (Russell et al. 2007), and their efficacy for malignant tumor-
associated hypercalcemia (Body et al.1999), ostealgia complicating bone metastasis of solid 
tumors (Hortobagyi et al. 1998), and multiple myeloma accompanied by bone destruction 
(Berenson et al. 1996) has been shown. Adverse effects of BPs were previously considered to 
be relatively mild, such as digestive symptoms induced by oral preparations and fever 
induced by injections (Berenson et al. 1996), but the association of BPs with osteonecrosis of 
the jaw has been frequently described since Marx (2003) initially reported it (Ruggiero et al. 
2004; Marx et al. 2005; Khosla et al. 2007) 
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is clinically diagnosed when the 
following 3 conditions are met: 1) current or previous treatment with BPs, 2) persistent 
exposure of necrotized bone in the maxillofacial region for 8 weeks or longer, 3) no past 
medical history of radiotherapy for the jaw bone (AAOMS 2007; Ruggiero et al. 2009). BPs 
inducing BRONJ mostly contain nitrogen (NBPs). BRONJ frequently develops in patients 
under NBP treatment upon dental treatment, such as tooth extraction, implant placement, 
and surgical periodontal treatment accompanied by bone invasion, and inflammatory 
diseases, such as periodontal disease and abscess (Ruggieri et al. 2009; Vahtsevanos et al. 
2009; Yoneda et al. 2010). BRONJ shows poor responses to the standard treatment for 
common osteomyelitis of the jaw, such as curettage/resection of necrotized tissue and 
antimicrobial drugs, and its intractability is the most serious problem.  
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Stack & Epker (1995) initially reported the influence of BPs on dental implant treatment. 
They introduced a case in which all 5 favorably functioning implants in the lower anterior 
tooth region were lost after the 5-month administration of a BP containing no nitrogen, 
etidronatedisodium (Didronel; Procter and Gamble, Cincinnati, OH), for osteoporosis. The 
details of the bone wound healing process after implant loss or whether BRONJ developed 
were not described, but the author concluded that Didronel administration is a risk factor 
for implant treatment. However, several recent studies reported that implant treatment in 
the presence of NBPs was possible when the NBPs were oral drugs. Fugazzotto et al (2007) 
evaluated that a retrospective analysis of case records of patients with a history of oral BPs 
therapy treated as part of routine periodontal and implant treatment. They reported that no 
osteonecrosis was noted immediately postoperatively or during follow-up period 61 
patients, and all implants were functioning successfully 12 to 24 months post-
insertion.Grant et al. (2008) evaluated the clinical results of 115 patients who received oral 
BPs during implant treatment. They showed that there was no significant difference in 
treatment results between patients with and without oral BPs during implant treatment. It 
was also reported that no patients developed ONJ after implant treatment. Bell & Bell (2008) 
reported that bone grafting for implant treatment in 42 patients who received oral BPs for 
osteoporosis treatment was conducted safely. Therefore, no conclusion has been reached 
regarding whether oral BPs are contraindicated for implant treatment. On the other hand, it 
has been clarified that the risk of developing BRONJ upon open dental treatment rises in 
patients treated with NBP intravenous injection showing a potent bone adsorption-
inhibitory action, and implant treatment is considered contraindicated for such cases (Khan 
et al. 2008; Ruggiero et al. 2009). However, there have been fewer reports on the influence of 
intravenous BPs on implants which have already acquired osseointegration and are 
favorably functioning, and the actual state is unclear.  
We experienced the case of a patient who developed ONJ around implants in the maxilla, 
considered to be caused by intravenous BP administration for osteometastasis treatment of 
breast cancer, and underwent partial maxillectomy to relieve inflammation (Shirota et al. 
2009). This chapter introduces clinical findings, the treatment and its outcome, and peri-
implant histopathological findings in the patient, and the developmental mechanism of peri-
implant BRONJ is discussed with a literature review.  
2. Patient and methods 
2.1 Outline of the patient 
The patient was a 54-year-old female who visited our hospital for chief complaints of peri-
implant pain in the upper left molar region and bone exposure. The patient developed 
breast cancer about 6 years ago and underwent left mastectomy followed by irradiation and 
chemotherapy. However, multiple cancer metastases occurred about 2 years ago, and the 
patient underwent cancer chemotherapy and intravenous BPs injection. 
The patient underwent implant treatment for the upper left molar region at a dental clinic 
immediately before the development of breast cancer, in which 2 implants were placed. 
These implants functioned without a problem for about 6 years, but peri-implant gingival 
recession, bone exposure, and pain appeared about one month ago, and the patient received 
antimicrobial drug administration, irrigation, and disinfection at a clinic, but the symptoms 
did not improve. Thus, the patient visited our department. On the first examination, brown-
colored necrotized bone was exposed in the upper left first molar region on the buccal side. 
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The peri-implant gingiva was painful and swollen with slight flare, but no implant mobility 
was observed (Fig.1). On panoramic radiography, mild bone resorption was noted in 
alveolar bone in the implant neck. Computed tomography (CT) revealed sequestration with 
an irregular trabecular bone structure around the implant (Fig.2). Biopsy was performed in 
consideration of metastasis of breast cancer to the oral cavity, but only inflammatory cell 
infiltration was observed without tumor cells.  
 
 
Fig. 1. Radiograph showing slight bone resorption around the implants. 
 
 
Fig. 2. Computed tomography (CT) image around the implants (arrow). 
2.2 Diagnosis and treatment  
It is well-known that curative chemotherapy or long-term adrenocortical steroid 
administration for lymphoblastic leukemia and Hodgkin and non-Hodgkin lymphomas 
induces osteonecrosis of the femoral head (Kubo et al. 2001; Bojko et al 2003; Karimova et al. 
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2008). Many anticancer drugs were administered for breast cancer metastasis in this patient, 
but no osteonecrosis of the jaw caused by these drugs has been reported. In addition, the 
clinical symptoms of this patient met all diagnostic criteria of BRONJ proposed by AAOMS 
(AAOMS 2007; Ruggiero et al. 2009). Based on these findings, BP-induced osteonecrosis was 
diagnosed.  
In the treatment, morbid bone tissue including implants was resected in consideration of the 
following 3 conditions: 1) early chemotherapy for metastatic cancer was necessary, for 
which removal of the infected lesion was necessary, 2) there was a possibility that 
continuation of the withdrawal of BPs would aggravate metastatic cancer-associated bone 
destruction and hypercalcemia, and 3) it was difficult to remit inflammation by employing 
conservative treatment proposed by the American Association of Oral and Maxillofacial 
Surgeons (AAOMS 2007; Ruggiero et al. 2009). After considering these points, 
sequestrectomy of the left maxilla was selected. The gingival margin was incised between 
the upper left first premolar and implant towards the maxillary tuberosity, and the lesion 
area was exposed by forming a buccal and palatal mucoperiosteal flap. The bone cortex of 
the lesion was brownish black, and necrotic bone was confirmed between the distal surface 
of the second premolar and mesial surface of the implant placed in the second molar area, 
but particularly around the implant placed in the first molar area (Fig.3a). The area for 
resection around the living bone in the lesion was determined after the extraction of the 
second premolar, and the pathological bone tissue including the implant was removed with 
a Lindeman bar and bone chisel, followed by the grinding of the bone surface of the 
resection stump until bleeding was confirmed. As a result, the instrument partially 
perforated the maxillary sinus floor, and the thickened maxillary sinus mucosa was 
exposed. This sinus mucosa was spared, and the surgical wound was completely closed by 
suturing the mucoperiosteal flaps (Fig.3b) 
 
 
(a) Pathological bone including the 
implants was removed, and maxillary 
sinus mucosa was exposed. 
(b) The surgical wound was completely 
closed by suturing the mucoperiosteal 
flap. 
Fig. 3. Intraoperative view of the sequestomy of the left maxilla. 
After surgery, antibiotic was intravenously administered for 3 days and oral antibiotic was 
administered for 3 days. In addition, hyperbaric oxygen therapy was performed. The efficacy 
of hyperbaric oxygen therapy for BRONJ is controversial (Ruggiero et al. 2004; Freiberger et al 
2009), but, at least, it may be effective to promote mucoepithelial wound healing in the 
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sequestration-resected region. The wound was completely covered with healthy mucosa 2 
weeks after surgery (Fig.4.). Since the remission of inflammation could be confirmed, 
anticancer drug and BP administration was initiated for metastatic cancer and bone 
metastasis-associated bone destruction. The patient died of multiorgan failure associated with 
multiple cancer metastasis 8 months after surgery, but BRONJ did not recur before death.  
 
 
Fig. 4. Intraoral view at 4 weeks after surgery. 
2.3 Macroscopic and CT findings of the resected specimen 
Implants were strongly fixed to the bone, and areas of brown sequestration were observed 
around them (Fig.5.). On CT, no apparent abnormality, such as trabecular destruction, was 




Fig. 5. The resected specimen shows a portion of the left maxilla including two implants. 
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Fig. 6. CT findings of the resected specimen.  
2.4 Histopathological analysis  
2.4.1 Histologic preparation 
The resected specimen was divided into the lesion including the implants and peri-lesion, 
i.e., healthy tissue in the resected stump. The bone tissue around the implants was fixed, 
dehydrated, and embedded in polyester resin (Ligorac®, Wako Pure Chemical Industries, 
Ltd., Tokyo, Japan). Undecalcified ground sections 15 m in thickness were cut along the 
long axis of the implant using the EXAKT Cutting-Grinding System (EXAKT, Norderstedt, 
Germany) and stained with 1% toluidine blue (pH 7.2), then the bone tissue around the 
implant was observed under light microscopy. Meanwhile, the bone tissue around the lesion 
was dehydrated and embedded in paraffin according to the conventional procedure. Some 
of the sections were stained with hematoxylin-eosin (HE) and AZAAN. Other sections were 
processed for immunohistochemical analysis by immunostaining with anti-human CD3, 
CD20, CD45 and CD68 (Daco, Carpinteria, CA). 
2.4.2 Peri-implant histopathological findings in undecalcified ground sections 
The implant surface was mostly in direct contact with bone tissue, suggesting that 
osseointegration was maintained until BRONJ development (Fig.7a). No osteocyte was present 
in the cavity of bone contacting implants or the surrounding trabeculae, nor were there cellular 
components on the bone surface, and bone tissue mostly showed sequestration (Fig.7b). The 
marrow cavity was filled with aggregates of actinomycete-like microorganisms, neutrophils, 
and other necrotized soft tissue (Fig.8a). In addition, adsorption cavities with a worm-eaten 
appearance were widely present. Normally, bone tissue necrotized in the body is absorbed by 
osteoclasts, shows sequestration, and is naturally excreted. However, no osteoclasts were 
present in the resorption cavity, suggesting that active resorption of the bone occurred in the 
BRONJ developmental process, rather than the resorption of necrotized bone by osteoclasts 
(Fig.8b). 
2.4.3 Histopathological findings around lesions in decalcified sections 
Osteocytes were present in the bone cavity (Fig.9a,b). The trabecular surface was smooth, 
and osteoid formation and osteoblast arrangement were observed. Reactive bone formation 
was also observed at various trabecular sites. Granulation tissue rich in capillary blood 
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(a) Most of the implant surfaces are in 
direct contact with the bone (× 40). 
(b) The bone in contact with the implant 
sureface is necrotic (× 200). 
Fig. 7. Histological findings of the tissue from the implants in an undecalcofied sections 
stained with toluidine blue. 
 
 
(a) Growth of a bacterial colony into the 
marrow cavity is observed (× 200). 
(b) Marked bone destruction with a moth 
eaten appearance is observed on the 
necrotic trabecular bone surface (× 200). 
Fig. 8. Histological findings of the tissue from the implants in an undecalcofied sections 
stained with toluidine blue. 
vessels invaded the bone marrow region (Fig.10a,b). On immunohistological staining, 
lymphocytes infiltrating the bone marrow were mostly CD3-positive, showing that the cells 
were derived from T cells. In contrast, only a few lymphoctyes were positive for CD20 and 
CD45 (Fig.11a,b), but they were considered not to be significant. Multinucleated giant cells 
strongly positive for CD68, assumed to be osteoclasts, were present at various sites on the 
trabecular surface (Fig.12a,b).  
3. Discussion on the peri-implant BRONJ developmental mechanism 
No viewpoint regarding the pathogenesis of BRONJ has been established. Based on clinical 
experience, mucosal injuries caused by poorly fitting dentures and oral surgical treatment, 
such as that for periodontal disease and tooth extraction, have been reported as local risk 
factors, but this patient received no surgical dental treatment during the BP administration 
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(a) The trabecular bone surface are 
smooth (HE stain; × 40) 
b) Growth of fibrous connective tissue 
and vascular formation are observed in 
the marrow(HE stain, × 100). 
Fig. 9. Histological findings of the tissue around the lesion in a decalcified thin section.  
 
 
(a) Numerous lymphoid cells are 
observed in the marrow (HE stain; × 200). 
(b) Lining cells and osteoid formation are 
observed (AZAN; × 100). 
Fig. 10. Histological findings of the tissue around the lesion in a decalcified thin section.  
 
 
(a) Many lymphoid cells are positive for 
anti-human CD3 (× 200). 
(b) Only a few lymphoctyes are positive 
for CD20 (× 200). 
Fig. 11. Immunohistological staining ot hte tissue around the lesion in a decalcified thin 
section. 
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(a) Only a few lymphoctyes are positive 
for CD45 (× 200). 
(b) Multinuclear cells are strongly positive 
for anti-human CD68 antibody (× 200). 
Fig. 12. Immunohistological staining ot hte tissue around the lesion in a decalcified thin 
section. 
period, and no implant mobility was observed in the BRONJ site. Histologically, 
oseointegration was widely maintained on the implant surface, and no deep overgrowth of 
gingival epithelium was noted, suggesting that BRONJ in this patient suddenly occurred 
around favorably functioning implants, and was not induced by peri-implant inflammation.  
Necrosis of the femoral head (Kerachian et al. 2006) and irradiation-induced osteonecrosis of 
the jaw (Marx 1983) are widely known as osteonecrotic lesions, and the cause is insufficiency 
of vascular formation in both diseases. Reportedly, zoledronate exhibits a potent 
vascularization-inhibitory effect (Giraudo et al. 2004), and the BP-induced obstruction of 
blood vessels in bone and necrosis of osteocytes around them have been reported (Hansen 
et al. 2007). Based on these findings, it is hypothesized that insufficiency of the blood supply 
is also involved in BRONJ, but, histologically, the absence of vascularization inhibition in 
BRONJ has been reported (Bedogni et al. 2008). Another important hypothesis suggests an 
influence of reduced bone remodeling due to the BP-induced inhibition of bone resorption 
by osteoclasts. It has been reported that osteocyte mortality increases when bone remodeling 
declines, i.e., BPs reduce bone remodeling, increasing osteocyte death, which is involved in 
BRONJ (Allen et al. 2009). However, many resorption cavities were present on the peri-
implant-sequestered bone surface, and the growth of granulation tissue containing 
abundant capillary blood vessels and reactive bone formation in the resected stump were 
confirmed in this patient. Thus, it is difficult to explain the cause of BRONJ with insufficient 
blood supply and the bone remodeling-inhibitory effect of BPs alone.  
Pamidronate and zoledronate administered intravenously to this patient are BPs that 
incorporate nitrogen. BPs containing nitrogen (NBPs) induce an inflammatory reaction by 
stimulating cells (Hewit et al. 2005; Endo et al. 1993; Nakamura et al. 1996). NBPs also exist 
on the surface of gram-negative cell walls, and increase inflammatory reactions to 
lipopolysaccharide (LPS), which has a strong inflammatory effect (Yamaguchi et al. 2000). 
Therefore, BRONJ may be caused by interactions among several factors differing among 
cases, not by a single cause. For example, in this patient, the following conditions may have 
influenced each other and caused BRONJ: 1) the excessive inhibition of bone turnover due to 
the NBP-related inhibition of bone resorption; 2) the occlusal force loaded on implants was 
directly transmitted to the bone, which activated local bone metabolism in the surrounding 
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region, releasing BP accumulated in the bone at a high level; 3) free NBP-induced 
inflammatory reactions, induction of osteoclast apoptosis (Roelofs et al. 2006), and inhibition 
of epithelial activity (Landesberg et al. 2009); 4) increased risk of bacterial infection due to 
suppression of the immune system; 5) enhanced inflammatory reactions due to interactions 
between gram-negative bacterial lipopolysaccharides and NBPs and 6) reduced local blood 
flow by vascularization inhibition and vascular obstruction (Fig.13). 
 
 
Fig. 13. Hypothetical mechanism of BRONJ aroud the implants. 
4. Conclusion 
BRONJ is intractable, and no treatment method has been established. Only guidelines 
mainly concerning prevention and conservative treatment have been proposed. When peri-
implant BRONJ occurs, firstly, conservative treatment should be selected following the 
AAOMS treatment guidelines, placing great importance on the prevention of exacerbation 
of BRONJ, but when NBPs are administered to control bone metastasis, it should be a 
priority to re-start BP administration and prevent any delay in cancer chemotherapy. 
Accordingly, although the appropriateness and timing of sequestration site resection should 
be carefully investigated, active surgical treatment may be one choice for some patients. 
Implant treatment is no longer special treatment. It is widely introduced into routine dental 
practice as a method to recover the occlusal function of defective teeth. Therefore, NBP 
intravenous injections will be increasingly administered to patients with a past medical 
history of implant treatment, for which the establishment of a practical clinical policy for the 
prevention and treatment of BRONJ is strongly desired.   
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